BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 15043023)

  • 1. [Therapy of malignant melanoma at the stage of distant metastasis].
    Garbe C; Eigentler TK
    Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of melanoma].
    Dréno B; Wallon-Dumont G
    Presse Med; 2003 Jan; 32(1):39-43. PubMed ID: 12610396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatments for advanced cutaneous melanoma.
    Anderson CM; Buzaid AC; Legha SS
    Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
    Terheyden P; Becker JC; Kämpgen E; Bröcker EB
    Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment and other combination regimens.
    Bajetta E; Del Vecchio M; Bajetta R; Canova S
    Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
    Ulrich J; Gademann G; Gollnick H
    J Neurooncol; 1999 Jun; 43(2):173-8. PubMed ID: 10533730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
    Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of uveal melanoma.
    Queirolo P; Acquati M
    Tumori; 2007; 93(3):suppl 27-30. PubMed ID: 17679486
    [No Abstract]   [Full Text] [Related]  

  • 9. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 10. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Hofmann MA; Sterry W; Trefzer U
    Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod in the treatment of metastatic melanoma to skin.
    Wolf IH; Smolle J; Binder B; Cerroni L; Richtig E; Kerl H
    Arch Dermatol; 2003 Mar; 139(3):273-6. PubMed ID: 12622616
    [No Abstract]   [Full Text] [Related]  

  • 12. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
    Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M
    Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 14. Metastatic melanoma: a regional review and future directions.
    Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
    Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
    Seeber A; Binder M; Steiner A; Wolff K; Pehamberger H
    Eur J Cancer; 1998 Dec; 34(13):2129-31. PubMed ID: 10070323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
    Hofmann M; Kiecker F; Wurm R; Schlenger L; Budach V; Sterry W; Trefzer U
    J Neurooncol; 2006 Jan; 76(1):59-64. PubMed ID: 16132502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P; Dreno B; Bureau B; Litoux P
    Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
    Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
    Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
    BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.